Gilead posts early Phase 1 data for once-yearly HIV PrEP therapy
Gilead (NASDAQ:GILD) on Tuesday announced encouraging initial data from an ongoing Phase 1 trial for lenacapavir, an ...
Fierce Biotech1d
Immunocore T-cell engager clears safety hurdle, reduces HIV reservoir in some patients
Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...
The Lancet5d
Research focus: Institute of HIV Research and Innovation
Founded 5 years ago, the Institute of HIV Research and Innovation works with communities to answer the research questions that matter most to them. Sima Barmania reports from Bangkok.
The American Journal of Managed Care5d
CROI 2025 Promises Breaking Results, Conversations Around HIV, COVID-19
This year’s Conference on Retroviruses and Opportunistic Infections (CROI) features several sessions discussing prevention ...